These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2896180)

  • 1. Muscles of diabetic (db/db) mice: fibre size, fibre type and the effects of a thermogenic, beta-adrenoceptor agonist.
    Almond RE; Cawthorne MA; Enser M
    Int J Obes; 1988; 12(1):81-91. PubMed ID: 2896180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of novel beta-adrenoceptor agonists on carbohydrate metabolism: relevance for the treatment of non-insulin-dependent diabetes.
    Cawthorne MA; Carroll MJ; Levy AL; Lister CA; Sennitt MV; Smith SA; Young P
    Int J Obes; 1984; 8 Suppl 1():93-102. PubMed ID: 6152558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of adrenalectomy on muscle fibre growth and fibre-type composition in obese-hyperglycaemic (ob/ob) and lean mice.
    Almond RE; Enser M
    Int J Obes; 1989; 13(6):791-800. PubMed ID: 2621052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced maximum capacity of glycolysis in brown adipose tissue of genetically obese, diabetic (db/db) mice and its restoration following treatment with a thermogenic beta-adrenoceptor agonist.
    Young P; Cawthorne MA; Levy AL; Wilson K
    FEBS Lett; 1984 Oct; 176(1):16-20. PubMed ID: 6149150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents.
    Arch JR; Ainsworth AT; Ellis RD; Piercy V; Thody VE; Thurlby PL; Wilson C; Wilson S; Young P
    Int J Obes; 1984; 8 Suppl 1():1-11. PubMed ID: 6152555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats.
    Arch JR; Ainsworth AT
    Am J Clin Nutr; 1983 Oct; 38(4):549-58. PubMed ID: 6137948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a novel thermogenic beta-adrenoceptor agonist (BRL 26830) on insulin resistance in soleus muscle from obese Zucker rats.
    Challiss RA; Budohoski L; Newsholme EA; Sennitt MV; Cawthorne MA
    Biochem Biophys Res Commun; 1985 Apr; 128(2):928-35. PubMed ID: 2986630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved glycemic control in C57Bl/KsJ (db/db) mice after treatment with the thermogenic beta-adrenoceptor agonist, BRL 26830.
    Carroll MJ; Lister CA; Sennitt MV; Stewart-Long N; Cawthorne MA
    Diabetes; 1985 Nov; 34(11):1198-204. PubMed ID: 2864298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of SR58611A, a potent beta-3 adrenoceptor agonist, on cutaneous wound healing in diabetic and obese mice.
    Schaeffer P; Bernat A; Arnone M; Manara L; Gallas JF; Dol-Gleizes F; Millet L; Grosset A; Herbert JM
    Eur J Pharmacol; 2006 Jan; 529(1-3):172-8. PubMed ID: 16325798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological and biochemical alterations of skeletal muscles from the genetically obese (ob/ob) mouse.
    Kemp JG; Blazev R; Stephenson DG; Stephenson GM
    Int J Obes (Lond); 2009 Aug; 33(8):831-41. PubMed ID: 19528970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A histochemical and morphological study of skeletal muscle from obese hyperglycaemic ob/ob mice.
    Almond RE; Enser M
    Diabetologia; 1984 Sep; 27(3):407-13. PubMed ID: 6238863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of streptozotocin-induced diabetes on growth and proteolytic activity of different muscles in rats.
    Chaudhury SK; Mandal MB; Deshpande SB; Saxena ID
    Indian J Exp Biol; 1994 Dec; 32(12):877-80. PubMed ID: 7896320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased insulin binding and glucose transport in white adipocytes isolated from C57B1/6 ob/ob mice treated with the thermogenic beta-adrenoceptor agonist BRL 26830.
    Young P; King L; Cawthorne MA
    Biochem Biophys Res Commun; 1985 Dec; 133(2):457-61. PubMed ID: 2867764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-obesity and anti-diabetic actions of a beta 3-adrenoceptor agonist, BRL 26830A, in yellow KK mice.
    Yoshida T; Hiraoka N; Yoshioka K; Hasegawa G; Kondo M
    Endocrinol Jpn; 1991 Aug; 38(4):397-403. PubMed ID: 1687027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of streptozotocin-induced diabetes on the number and diameter of fibres in different skeletal muscles of the rat.
    Hegarty PV; Rosholt MN
    J Anat; 1981 Sep; 133(Pt 2):205-11. PubMed ID: 7333950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on skeletal muscle fibres of diabetes and Ginkgo biloba extract treatment.
    Punkt K; Psinia I; Welt K; Barth W; Asmussen G
    Acta Histochem; 1999 Feb; 101(1):53-69. PubMed ID: 10093642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-endorphin and corticotropin immunoreactivity and specific binding in the neuromuscular system of obese-diabetic mice.
    Hughes S; Smith ME; Bailey CJ
    Neuroscience; 1992; 48(2):463-8. PubMed ID: 1318515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-hyperglycaemic action of BRL 26830, a novel beta-adrenoceptor agonist, in mice and rats.
    Sennitt MV; Arch JR; Levy AL; Simson DL; Smith SA; Cawthorne MA
    Biochem Pharmacol; 1985 Apr; 34(8):1279-85. PubMed ID: 2859857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic effects of three weeks administration of the beta-adrenoceptor agonist BRL 26830A.
    Connacher AA; Bennet WM; Jung RT; Rennie MJ
    Int J Obes Relat Metab Disord; 1992 Sep; 16(9):685-94. PubMed ID: 1356939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice.
    Bryson JM; Wensley VR; Phuyal JL; Caterson ID; Cooney GJ
    Horm Metab Res; 1999 May; 31(5):317-22. PubMed ID: 10422727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.